{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:09:18Z","timestamp":1777396158058,"version":"3.51.4"},"reference-count":15,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2022,11,22]]},"abstract":"<jats:p>A blood test for Alzheimer\u2019s disease is now available for clinical use in persons with cognitive impairment. This is an extraordinary milestone, though the amyloid-based PrecivityAD\u2122 test is not without limitations. Pre and post-test counseling are essential. Phosphorylated tau blood tests are likely to follow soon. When used in conjunction with an appropriate clinical evaluation, blood tests provide the opportunity for an early, accurate, and accessible diagnosis of Alzheimer\u2019s disease. Standalone use, however, carries a significant risk of misinterpretation and is strongly discouraged. Now is the time to develop appropriate use criteria to guide the use of these promising assays.<\/jats:p>","DOI":"10.3233\/jad-215490","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T10:38:59Z","timestamp":1644575939000},"page":"963-966","source":"Crossref","is-referenced-by-count":6,"title":["A Blood Test for Alzheimer\u2019s Disease: It\u2019s about Time or Not Ready for Prime Time?"],"prefix":"10.1177","volume":"90","author":[{"given":"Douglas R.","family":"Galasko","sequence":"first","affiliation":[{"name":"Department of Neurosciences, University of California San Diego, La Jolla, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"and for the Symptomatic Subcommittee of the Advisory Group on Risk Evidence Education for Dementia (AGREEDementia)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua D.","family":"Grill","sequence":"additional","affiliation":[{"name":"Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer H.","family":"Lingler","sequence":"additional","affiliation":[{"name":"Department of Health and Community Systems, University of Pittsburgh School of Nursing, Pittsburgh, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith L.","family":"Heidebrink","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Michigan, Ann Arbor, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-215490_ref2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/ana.25968","article-title":"Diagnostic accuracy of amyloid versus 18 F-fluorodeoxyglucose positron emission tomography in autopsy-confirmed dementia","volume":"89","author":"Lesman-Segev","year":"2021","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-215490_ref3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","article-title":"Advantages and disadvantages of the use of the CSF amyloid \u03b2 (A\u03b2) 42\/40 ratio in the diagnosis of Alzheimer\u2019s disease","volume":"11","author":"Hansson","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-215490_ref4","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2019.2000","article-title":"Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia","volume":"321","author":"Rabinovici","year":"2019","journal-title":"JAMA"},{"key":"10.3233\/JAD-215490_ref5","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebralamyloid pathology in persons without dementia: A meta-analysis","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"},{"key":"10.3233\/JAD-215490_ref6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00401-017-1717-7","article-title":"Impact of multiple pathologies on the threshold for clinically overt dementia","volume":"134","author":"Kapasi","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-215490_ref7","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2967\/jnumed.113.120618","article-title":"Appropriate use criteria for amyloid PET: A reportof the Amyloid Imaging Task Force, the Society of Nuclear Medicine and MolecularImaging, and the Alzheimer\u2019s Association","volume":"54","author":"Johnson","year":"2013","journal-title":"J Nucl Med"},{"key":"10.3233\/JAD-215490_ref8","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jalz.2018.07.220","article-title":"Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer\u2019s disease","volume":"14","author":"Shaw","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-215490_ref9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-020-00763-7","article-title":"Biomarker testing in MCI patients-deciding who to test","volume":"13","author":"van Maurik","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-215490_ref10","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/ene.14668","article-title":". European Academy of Neurology\/European Alzheimer\u2019s Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment","volume":"28","author":"Frederiksen","year":"2021","journal-title":"Eur J Neurol"},{"key":"10.3233\/JAD-215490_ref11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","article-title":"Plasma p-tau181 accurately predicts Alzheimer\u2019s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline","volume":"140","author":"Lantero Rodriguez","year":"2020","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-215490_ref12","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"10.3233\/JAD-215490_ref13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: A new biomarker for incipient Alzheimer\u2019s disease pathology","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-215490_ref14","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12466"},{"key":"10.3233\/JAD-215490_ref15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s43587-020-00003-5","article-title":"Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations","volume":"1","author":"Cullen","year":"2021","journal-title":"Nat Aging"},{"key":"10.3233\/JAD-215490_ref16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13024-021-00451-6","article-title":"A blood-based diagnostic test incorporating plasma A\u03b242\/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: Findings from a multi cohort validity analysis","volume":"16","author":"West","year":"2021","journal-title":"Mol Neurodegener"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-215490","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:07:42Z","timestamp":1777370862000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-215490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":15,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jad-215490","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]}}}